John Tsai, Head of Global Drug Development and Chief Medical Officer, describes how he balances innovation and patient needs.

Jay Bradner discusses his vision for an open framework of scientific discovery at Novartis.

The race is on to find a new treatment before resistance to today’s drugs becomes widespread.

Jennifer Leeds offers a behind-the-scenes look at the consortia forming to address COVID-19.

Functional genomics study reveals a potential approach for tackling glioblastoma, pancreatic cancer and other tumors.

For over 60 years Novartis has been committed to helping people with cardiovascular disease and we remain steadfast in that commitment to this day.